Suppr超能文献

5'-(-乙基甲酰胺基)腺苷类似物作为Grp94选择性抑制剂的生物学评价

Biological Evaluation of 5'-(-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors.

作者信息

Tosh Dilip K, Brackett Christopher M, Jung Young-Hwan, Gao Zhan-Guo, Banerjee Monimoy, Blagg Brian S J, Jacobson Kenneth A

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.

出版信息

ACS Med Chem Lett. 2021 Mar 1;12(3):373-379. doi: 10.1021/acsmedchemlett.0c00509. eCollection 2021 Mar 11.

Abstract

The heat shock protein 90 kDa (Hsp90) family of chaperones is highly sought-after for the treatment of cancer and neurodegenerative diseases. Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum localized isoform that is responsible for the maturation of proteins involved in cell adhesion and the immune response, including Toll-like receptors, immunoglobulins, and integrins. Consequently, Grp94 has been implicated in many different diseases including cancer metastasis, glaucoma, and viral infection. 5'-(-Ethylcarboxamido)adenosine (NECA) was identified from a high-throughput screen as one of the first molecules to exhibit isoform selectivity toward Grp94, with the ethyl group projecting into a unique pocket within the ATP binding site of Grp94. This pocket has since been exploited by several groups to develop Grp94 selective inhibitors. Despite success in the development of other classes of inhibitors, relatively little work has been done to further develop inhibitors with the NECA scaffold. Unfortunately, NECA is also a potent adenosine receptor agonist, which is likely to confound any biological activity. Therefore, structure-activity relationship studies were performed on the NECA scaffold leading to the discovery of several molecules that displayed similar selectivity and affinity as the parent compound.

摘要

伴侣蛋白90千道尔顿热休克蛋白(Hsp90)家族在癌症和神经退行性疾病治疗方面备受关注。葡萄糖调节蛋白94(Grp94)是内质网定位的异构体,负责参与细胞黏附和免疫反应的蛋白质成熟,包括Toll样受体、免疫球蛋白和整合素。因此,Grp94与许多不同疾病有关,包括癌症转移、青光眼和病毒感染。5'-(-乙基甲酰胺基)腺苷(NECA)是通过高通量筛选鉴定出的首批对Grp94表现出异构体选择性的分子之一,其乙基伸入Grp94 ATP结合位点内的一个独特口袋。此后,几个研究小组利用这个口袋开发了Grp94选择性抑制剂。尽管在开发其他类型抑制剂方面取得了成功,但在进一步开发具有NECA支架的抑制剂方面所做的工作相对较少。不幸的是,NECA也是一种强效腺苷受体激动剂,这可能会混淆任何生物学活性。因此,对NECA支架进行了构效关系研究,发现了几种与母体化合物具有相似选择性和亲和力的分子。

相似文献

1
Biological Evaluation of 5'-(-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors.
ACS Med Chem Lett. 2021 Mar 1;12(3):373-379. doi: 10.1021/acsmedchemlett.0c00509. eCollection 2021 Mar 11.
2
NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90.
J Biol Chem. 2019 Nov 1;294(44):16010-16019. doi: 10.1074/jbc.RA119.009960. Epub 2019 Sep 9.
3
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold.
J Med Chem. 2016 Apr 14;59(7):3471-88. doi: 10.1021/acs.jmedchem.6b00085. Epub 2016 Apr 4.
4
Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
ACS Chem Biol. 2017 Jan 20;12(1):244-253. doi: 10.1021/acschembio.6b00747. Epub 2016 Dec 13.
5
Investigation of the site 2 pocket of Grp94 with KUNG65 benzamide derivatives.
Bioorg Med Chem Lett. 2024 Oct 1;111:129893. doi: 10.1016/j.bmcl.2024.129893. Epub 2024 Jul 21.
7
5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.
Protein Sci. 2016 Dec;25(12):2209-2215. doi: 10.1002/pro.3049. Epub 2016 Oct 4.
8
Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer.
Chemistry. 2017 Nov 7;23(62):15775-15782. doi: 10.1002/chem.201703398. Epub 2017 Sep 27.
9
Selective inhibition of hsp90 paralogs: Uncovering the role of helix 1 in Grp94-selective ligand binding.
bioRxiv. 2024 Aug 19:2023.07.31.551342. doi: 10.1101/2023.07.31.551342.

引用本文的文献

1
Hsp90 and Isoform-Selective Inhibitors as Sensitizers for Cancer Immunotherapy.
Pharmaceuticals (Basel). 2025 Jul 10;18(7):1025. doi: 10.3390/ph18071025.
2
Advances in the structures, mechanisms and targeting of molecular chaperones.
Signal Transduct Target Ther. 2025 Mar 12;10(1):84. doi: 10.1038/s41392-025-02166-2.
3
Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors.
ACS Med Chem Lett. 2025 Jan 22;16(2):301-310. doi: 10.1021/acsmedchemlett.4c00550. eCollection 2025 Feb 13.
5
N-Glycosylation-Induced Pathologic Protein Conformations as a Tool to Guide the Selection of Biologically Active Small Molecules.
Chemistry. 2024 Sep 25;30(54):e202401957. doi: 10.1002/chem.202401957. Epub 2024 Sep 9.
6
How aberrant N-glycosylation can alter protein functionality and ligand binding: An atomistic view.
Structure. 2023 Aug 3;31(8):987-1004.e8. doi: 10.1016/j.str.2023.05.017. Epub 2023 Jun 20.
8
Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence.
Cancer Metastasis Rev. 2023 Mar;42(1):217-254. doi: 10.1007/s10555-023-10085-3. Epub 2023 Feb 1.
9
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?
Int J Mol Sci. 2021 Nov 22;22(22):12569. doi: 10.3390/ijms222212569.
10
Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.
RSC Med Chem. 2021 Jul 13;12(11):1808-1825. doi: 10.1039/d1md00167a. eCollection 2021 Nov 17.

本文引用的文献

1
Overexpression of molecule GRP94 favors tumor progression in lung adenocarcinoma by interaction with regulatory T cells.
Thorac Cancer. 2020 Mar;11(3):704-712. doi: 10.1111/1759-7714.13321. Epub 2020 Jan 22.
3
NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90.
J Biol Chem. 2019 Nov 1;294(44):16010-16019. doi: 10.1074/jbc.RA119.009960. Epub 2019 Sep 9.
4
Multiple adenosine receptor subtypes stimulate wound healing in human EA.hy926 endothelial cells.
Purinergic Signal. 2019 Sep;15(3):357-366. doi: 10.1007/s11302-019-09668-z. Epub 2019 Jun 28.
5
Glucose-regulated protein of 94 kDa contributes to the development of an aggressive phenotype in breast cancer cells.
Biomed Pharmacother. 2018 Sep;105:115-120. doi: 10.1016/j.biopha.2018.05.106. Epub 2018 May 28.
6
Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.
J Med Chem. 2018 Apr 12;61(7):2793-2805. doi: 10.1021/acs.jmedchem.7b01608. Epub 2018 Mar 20.
7
Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
Nat Commun. 2018 Jan 30;9(1):425. doi: 10.1038/s41467-017-02013-1.
8
Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.
J Med Chem. 2017 Sep 14;60(17):7569-7578. doi: 10.1021/acs.jmedchem.7b00978. Epub 2017 Aug 30.
9
5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.
Protein Sci. 2016 Dec;25(12):2209-2215. doi: 10.1002/pro.3049. Epub 2016 Oct 4.
10
Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Curr Pharm Des. 2016;22(20):2947-59. doi: 10.2174/1381612822666160325152200.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验